Fig. 4
Effects of SDV on hippocampal TrkB/BDNF signaling in LPS-challenged mice treated with rhANP. a, b Western blot analysis of phosphorylated/total tyrosine kinase receptor B ratio (p-TrkB/t-total) in the hippocampus (one-way ANOVA: F2,27 = 5.245, P = 0.0119) and prefrontal cortex (PFC) (one-way ANOVA: F2,27 = 0.2589, P = 0.7738) of mice treated with recombinant human ANP (rhANP) or 0.9% saline 24 h after injection of lipopolysaccharides (LPS) or 0.9% saline. c, d Western blot analysis of p-TrkB/t-total in the hippocampus (two-way ANOVA: rhANP: F1,36 = 1.633, P = 0.2095; SDV: F1,36 = 9.169, P = 0.0045; interaction: F1,36 = 4.395, P = 0.0431) and PFC (two-way ANOVA: rhANP: F1,36 = 0.1409, P = 0.7096; SDV: F1,36 = 0.3043, P = 0.5846; interaction: F1,36 = 0.2733, P = 0.6044) of rhANP or 0.9% saline-treated endotoxemia mice pre-subjected to SDV or sham operation. e, f Western blot analysis of BDNF in the hippocampus (one-way ANOVA: F2,27 = 12.20, P = 0.0002) and PFC (one-way ANOVA: F2,27 = 2.218, P = 0.1290) of mice treated with rhANP or 0.9% saline 24 h after injection of LPS or 0.9% saline. g, h Western blot analysis of BDNF in the hippocampus (two-way ANOVA: rhANP: F1,36 = 6.305, P = 0.0167; SDV: F1,36 = 2.378, P = 0.1318; interaction: F1,36 = 5.767, P = 0.0216) and PFC (two-way ANOVA: rhANP: F1,36 = 0.2615, P = 0.6122; SDV: F1,36 = 0.1217, P = 0.7292; interaction: F1,36 = 0.1715, P = 0.6813) of rhANP or 0.9% saline-treated endotoxemia mice pre-subjected to SDV or sham operation. Data are shown as mean ± SEM, n = 10/group. *P < 0.05, **P < 0.01, ***P < 0.0001; N.S. not significant. SDV subdiaphragmatic vagotomy